By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Visterra, Inc. 

One Kendall Square
Suite B3301
Cambridge  Massachusetts  02139  U.S.A.
Phone: 617-498-1070 Fax: 617-498-1073


SEARCH JOBS


Industry
Biotechnology






Company News
Cambridge Biotech Visterra Scuttles Plans for $50 Million IPO 2/13/2017 6:39:15 AM
Visterra, Inc. Release: Pharma Doses First Patient In Phase 2a Trial For VIS410, Its Monoclonal Antibody In Development For The Treatment Of Hospitalized Patients With Influenza A 1/11/2017 9:56:10 AM
Visterra, Inc. Gears Up For IPO 12/27/2016 12:40:03 PM
Visterra, Inc. To Present New Clinical Results Of VIS410 At The Options IX For The Control Of Influenza Conference 8/25/2016 11:21:51 AM
Visterra, Inc. To Present New Clinical Results Of VIS410 At The Options IX For The Control Of Influenza Conference 8/24/2016 11:26:36 AM
Visterra, Inc. Appoints Two Industry Leaders To Its Board Of Directors 4/21/2016 11:03:44 AM
Visterra, Inc. Announces Publication Of Clinical Data On VIS410 In The Journal EBioMedicine 2/26/2016 8:22:36 AM
Visterra, Inc.’s Monoclonal Antibody In Development For The Treatment Of Influenza A, VIS410, Demonstrated Significant Antiviral Activity And Reduced Duration Of Respiratory Symptoms In Phase IIa Challenge Study 10/5/2015 10:31:10 AM
Visterra, Inc. Awarded Contract Valued at Up to $204.5 Million 10/5/2015 8:24:44 AM
Visterra, Inc. And Serum Institute of India, Ltd. Announce Collaboration To Advance VIS513, A Monoclonal Antibody In Development For The Treatment Of Dengue, In The Indian Subcontinent 9/9/2015 11:18:31 AM
123
//-->